This study is looking at how well adding a drug called panitumumab to regular chemotherapy helps treat a type of pancreatic cancer. This cancer is called pancreatic ductal adenocarcinoma. Some people with this cancer have a special type called KRAS wild type (WT), which means their cancer doesn't have a certain mutation. Panitumumab is a *monoclonal antibody*, a protein that can attach to cancer cells and may stop them from growing. The study will compare standard chemotherapy alone to chemotherapy with panitumumab to see which works better. Chemotherapy includes medicines like *nanoliposomal irinotecan*, *leucovorin*, and *5-fluorouracil (5-FU)*.

• Participation Duration: The study lasts for up to 3 years, with regular check-ups and scans.
• Treatments: Participants receive chemotherapy and possibly panitumumab every 28 days.
• Potential Risks: There may be side effects from panitumumab and chemotherapy (like fatigue or nausea).

Participants must have a confirmed diagnosis of this type of cancer and meet other health criteria. It's important to discuss with a doctor if this study is a good fit.